{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:51:03Z","timestamp":1773957063305,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Dual blockade of IL-4 and IL-13 in atopic dermatitis (AD) has been associated with activation of the IL-23\/IL-17 axis, potentially leading to paradoxical psoriasis and PsA-like presentation. However, the specific cytokine responsible for these reactions remains unclear. We report a case series of PsA-like presentation following treatment with tralokinumab, an anti-IL-13 monoclonal antibody used for AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified four patients who developed a PsA-like presentation affecting the joints, entheses, and, in some instances, the skin, following tralokinumab initiation for AD. Clinical features, laboratory findings, imaging results and treatment outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 139 patients treated with tralokinumab across two large UK referral centres, four developed new-onset PsA-like presentation with inflammatory arthritis and enthesitis that emerged after tralokinumab initiation. All four had previously failed dupilumab therapy. Skin biopsies and joint imaging confirmed PsA-like features. Symptoms began weeks to months after starting tralokinumab and resolved following treatment withdrawal or modification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first case series documenting arthritis and enthesitis associated with anti-IL-13 therapy, suggesting a potential pathogenetic role of IL-13 inhibition in the development of PsA-like presentation. These findings warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf657","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:34:33Z","timestamp":1765197273000},"source":"Crossref","is-referenced-by-count":1,"title":["Development of a PsA-like presentation under anti-IL-13 therapy with tralokinumab for atopic dermatitis"],"prefix":"10.1093","volume":"65","author":[{"given":"Katya","family":"Meridor","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]},{"name":"Rheumatology Department, Tel Aviv Sourasky Medical Center, affiliated with Tel Aviv University Faculty of Medicine , Tel Aviv,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook Yan","family":"Lee","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Blee","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane E","family":"Freeston","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-0699","authenticated-orcid":false,"given":"Philip M","family":"Laws","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2406-161X","authenticated-orcid":false,"given":"Gabriele","family":"De Marco","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerem","family":"Abacar","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Macleod","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Rowbotham","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]},{"name":"Musculoskeletal Radiology Department, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Di Matteo","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Woolf","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pink","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Kirkham","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds,","place":["UK"]},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026031913414657400_keaf657-B1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026031913414657400_keaf657-B2","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2026031913414657400_keaf657-B3","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.42558","article-title":"Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an interleukin-4\/13 inhibitor","volume":"75","author":"Hughes","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026031913414657400_keaf657-B4","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/ced.15130","article-title":"Paradoxical eczema in patients with psoriasis receiving biologics: a case series","volume":"47","author":"Al-Janabi","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2026031913414657400_keaf657-B5","doi-asserted-by":"crossref","first-page":"101520","DOI":"10.1016\/j.smim.2021.101520","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","volume":"58","author":"Bridgewood","year":"2021","journal-title":"Semin Immunol"},{"key":"2026031913414657400_keaf657-B6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026031913414657400_keaf657-B7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2026031913414657400_keaf657-B8","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026031913414657400_keaf657-B9","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026031913414657400_keaf657-B10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2010.11.043","article-title":"Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production","volume":"127","author":"Newcomb","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2026031913414657400_keaf657-B11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/ard.2010.143123","article-title":"Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026031913414657400_keaf657-B12","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.42942","article-title":"Genetically proxied interleukin-13 inhibition is associated with risk of psoriatic disease: a mendelian randomization study","volume":"76","author":"Zhao","year":"2024","journal-title":"arthritis Rheumatol"},{"key":"2026031913414657400_keaf657-B13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031913414657400_keaf657-B14","doi-asserted-by":"crossref","first-page":"1631321","DOI":"10.3389\/fphar.2025.1631321","article-title":"Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness","volume":"16","author":"Ameer","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026031913414657400_keaf657-B15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ijd.17397","article-title":"Tralokinumab-induced psoriasis relapse in a patient with atopic dermatitis","volume":"64","author":"Chiei Gallo","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026031913414657400_keaf657-B16","doi-asserted-by":"crossref","first-page":"2258240","DOI":"10.1080\/09546634.2023.2258240","article-title":"Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis","volume":"34","author":"Balakirski","year":"2023","journal-title":"J Dermatol Treat"},{"key":"2026031913414657400_keaf657-B17","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14712598.2023.2292627","article-title":"Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study","volume":"23","author":"Chiricozzi","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2026031913414657400_keaf657-B18","doi-asserted-by":"crossref","first-page":"2285243","DOI":"10.1080\/09546634.2023.2285243","article-title":"Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience","volume":"34","author":"Ferrucci","year":"2023","journal-title":"J Dermatol Treat"},{"key":"2026031913414657400_keaf657-B19","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/jdv.19382","article-title":"Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study","volume":"38","author":"Pezzolo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf657\/65823730\/keaf657.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/3\/keaf657\/65823730\/keaf657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/3\/keaf657\/65823730\/keaf657.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:41:55Z","timestamp":1773942115000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf657\/8375718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf657","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,9]]},"article-number":"keaf657"}}